GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Affymetrix Inc (NAS:AFFX) » Definitions » EBITDA

Affymetrix (Affymetrix) EBITDA : $39.3 Mil (TTM As of Dec. 2015)


View and export this data going back to . Start your Free Trial

What is Affymetrix EBITDA?

Affymetrix's EBITDA for the three months ended in Dec. 2015 was $11.6 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2015 was $39.3 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Affymetrix's EBITDA per Share for the three months ended in Dec. 2015 was $0.14. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2015 was $0.46.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Affymetrix EBITDA Historical Data

The historical data trend for Affymetrix's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymetrix EBITDA Chart

Affymetrix Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.37 -3.29 36.53 33.45 39.29

Affymetrix Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.17 12.13 14.14 1.43 11.60

Competitive Comparison of Affymetrix's EBITDA

For the Diagnostics & Research subindustry, Affymetrix's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymetrix's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Affymetrix's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Affymetrix's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Affymetrix's EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Affymetrix's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2015, Affymetrix's EBITDA was $39.3 Mil.

Affymetrix's EBITDA for the quarter that ended in Dec. 2015 is calculated as

Affymetrix's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2015, Affymetrix's EBITDA was $11.6 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Affymetrix  (NAS:AFFX) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Affymetrix EBITDA Related Terms

Thank you for viewing the detailed overview of Affymetrix's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymetrix (Affymetrix) Business Description

Traded in Other Exchanges
N/A
Address
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
Executives
Nelson C Chan director C/O SYNAPTICS INCORPORATED, 1251 MCKAY DRIVE, SAN JOSE CA 95131
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Gary S Guthart director C/O INTUITIVE SURGICAL INC, 1266 KIFER RD, SUNNYVALE CA 94086
Jami K Nachtsheim director
Riccardo Pigliucci director 9640 TOWNE CENTRE DR, SAN DIEGO CA 92121
Andrew J. Last officer: EVP, Chief Operating Officer 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Gavin Wood officer: EVP, Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Frank Witney director, officer: President and CEO 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Fodor Stephen P A director C/O AFFYMETRIX INC, 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Robert Paul Wayman director C/O HEWLETT-PACKARD COMPANY, 3000 HANOVER STREET, PALO ALTO CA 94304
Timothy C Barabe officer: Chief Financial Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Runkel John F Jr officer: EVP and General Counsel C/O INTUITIVE SURGICAL, INC., 1266 KIFER ROAD, SUNNYVALE CA 94086
John D Diekman director C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kevin M King officer: President and CEO C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Paul Berg director STANFORD UNIVERSITY SCHOOL OF MEDICINE, #B062, STANFORD CA 94305

Affymetrix (Affymetrix) Headlines

From GuruFocus

Affymetrix Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-06-2010

Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 08-24-2010

Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 11-19-2010